Literature DB >> 7036725

Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies.

D Batlle, K Itsarayoungyuen, J A Arruda, N A Kurtzman.   

Abstract

This report describes the occurrence of hyperkalemic hyperchloremic metabolic acidosis in six patients with sickle cell hemoglobinopathies. Three patients had sickle cell anemia, two had sickle cell trait and one had S-C disease. In all patients, decreased renal potassium excretion was demonstrated by the finding of a fractional potassium excretion lower than that of control subjects with comparable glomerular filtration rates. Two patterns of impaired urinary acidification were discerned. Four patients had a urinary pH above 5.5 in the presence of systemic acidosis and, thus, were classified a having distal renal tubular acidosis. The remaining two patients had very low rates of ammonium excretion despite intact capacity to lower urinary pH below 5.5 during systemic acidosis; this pattern was ascribed to selective aldosterone deficiency. Sickle cell hemoglobinopathies should be included in the differential diagnosis of hyperkalemic hyperchloremic metabolic acidosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7036725     DOI: 10.1016/0002-9343(82)90809-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

Review 1.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

2.  Prevalence and correlates of metabolic acidosis among patients with homozygous sickle cell disease.

Authors:  Stéphane Maurel; Katia Stankovic Stojanovic; Virginie Avellino; Alexey Girshovich; Emmanuel Letavernier; Gilles Grateau; Laurent Baud; Robert Girot; Francois Lionnet; Jean-Philippe Haymann
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

Review 3.  Sickle cell nephropathy: challenging the conventional wisdom.

Authors:  Amy M Becker
Journal:  Pediatr Nephrol       Date:  2011-01-04       Impact factor: 3.714

4.  Anaesthesia for renal transplantation in sickle cell disease.

Authors:  H K Gyasi; A W Zarroug; M Matthew; R Joshi; A Daar
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

5.  Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia.

Authors:  Santosh L Saraf; Xu Zhang; Tamir Kanias; James P Lash; Robert E Molokie; Bharvi Oza; Catherine Lai; Julie H Rowe; Michel Gowhari; Johara Hassan; Joseph Desimone; Roberto F Machado; Mark T Gladwin; Jane A Little; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2013-12-12       Impact factor: 6.998

6.  Hyperkalemic distal renal tubular acidosis associated with Rett syndrome.

Authors:  Farahnak Assadi; Colleen Crowe; Omid Rouhi
Journal:  Pediatr Nephrol       Date:  2006-03-02       Impact factor: 3.714

Review 7.  Renal tubular hyperkalaemia in childhood.

Authors:  J Rodríguez-Soriano; A Vallo
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

8.  Differential diagnosis of hyperkalemia: an update to a complex problem.

Authors:  T Eleftheriadis; K Leivaditis; G Antoniadi; V Liakopoulos
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

9.  Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC.

Authors:  Paul Drawz; Sabarish Ayyappan; Mehdi Nouraie; Santosh Saraf; Victor Gordeuk; Thomas Hostetter; Mark T Gladwin; Jane Little
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-15       Impact factor: 8.237

10.  Tubular Acidification Defect in Adults with Sickle Cell Disease.

Authors:  Maud Cazenave; Vincent Audard; Jean-Philippe Bertocchio; Anoosha Habibi; Stéphanie Baron; Caroline Prot-Bertoye; Jugurtha Berkenou; Gérard Maruani; Thomas Stehlé; Nicolas Cornière; Hamza Ayari; Gérard Friedlander; Frédéric Galacteros; Pascal Houillier; Pablo Bartolucci; Marie Courbebaisse
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-10       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.